70362-07-1

Basic information

• Product Name: 2-hydroxy-4-Morpholinobenzaldehyde
• Synonyms: 2-hydroxy-4-Morpholinobenzaldehyde
• CAS NO: 70362-07-1
• Molecular Formula: C₁₁H₁₃NO₃
• Molecular Weight: 207.22582
• Mol File: 70362-07-1.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 401.3±45.0 °C(Predicted)
• Appearance: /
• Density: 1.272±0.06 g/cm3(Predicted)
• PKA: 8.48±0.10(Predicted)
• CAS DataBase Reference: 2-hydroxy-4-Morpholinobenzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2-hydroxy-4-Morpholinobenzaldehyde(70362-07-1)
• EPA Substance Registry System: 2-hydroxy-4-Morpholinobenzaldehyde(70362-07-1)

Safety Data

• Hazardous Substances Data: 70362-07-1(Hazardous Substances Data)

Usage

Description

DNA-PK inhibitor IV is an inhibitor of DNA-dependent protein kinase (DNA-PK) with an IC50 value of 400 nM for the DNA-PK-dependent phosphorylation of a p53 peptide substrate. It also inhibits the phosphatidylinositol 3-kinase (PI3K) isoforms p110β, p110δ, and p110γ (IC50s = 2.8, 5.1, and 37 nM, respectively) but not p110α (IC50 = ~10 μM) or class II PI3Ks, PI4Kβ, ATM, ATR, mTOR, CK2, or GRK2 (IC50s = >50 μM). It enhances radiation-induced cytotoxicity of HCT116 cells when used at a concentration of 100 μM.

Upstream product

• 27292-49-5 3-(4-morpholino)phenol 
• 68-12-2 N,N-dimethyl-formamide 
• 925-90-6 ethylmagnesium bromide 
• 591-27-5 m-Hydroxyaniline 
• 110-91-8 morpholine 
• 348-28-7 4-fluoro-2-hydroxybenzaldehyde 

Downstream Products

• 404009-40-1 IC₈₆₆₂₁ 
• 404009-46-7 AMA₃₇ 

Relevant articles and documents

Piperazine-Coumarin based fluorescence probe with enhanced brightness and solubility for bio-thiol detection and esophageal carcinoma diagnosis

The development of novel fluorescent dyes for bio-thiol is of great importance in biological, clinical and pharmaceutical sciences. Given the importance of bio-thiol anticipating in numerous physiological processes, there is a great need to construct fluo

Synthesis and pharmacological evaluation of carboxycoumarins as a new antitumor treatment targeting lactate transport in cancer cells

Under hypoxia, cancer cells consume glucose and release lactate at a high rate. Lactate was recently documented to be recaptured by oxygenated cancer cells to fuel the TCA cycle and thereby to support tumor growth. Monocarboxylate transporters (MCT) are the main lactate carriers and therefore represent potential therapeutic targets to limit cancer progression. In this study, we have developed and implemented a stepwise in vitro screening procedure on human cancer cells to identify new potent MCT inhibitors. Various 7-substituted carboxycoumarins and quinolinone derivatives were synthesized and pharmacologically evaluated. Most active compounds were obtained using a palladium-catalyzed Buchwald-Hartwig type coupling reaction, which proved to be a quick and efficient method to obtain aminocarboxycoumarin derivatives. Inhibition of lactate flux revealed that the most active compound 19 (IC 50 11 nM) was three log orders more active than the CHC reference compound. Comparison with warfarin, a conventional anticoagulant coumarin, further showed that compound 19 did not influence the prothrombin time which, together with a good in vitro ADME profile, supports the potential of this new family of compounds to act as anticancer drugs through inhibition of lactate flux.

Benzofurylpyrone derivatives

There is provided benzofuryl-α-pyrone derivative represented by the following structural formula (I): wherein R1represents a hydrogen atom or an alkyl group of 1 to 5 carbons; R2represents hydrogen, —CO—R5or —SO2/sub